Therapeutic uses of antiepileptic drugs in non-epileptic disorders

SA Pharmaceutical Journal

Volumn 77, Issue 5, 2010, Pages 18-27

  Moch, Shirra ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CARBAPENEM; CARDIOVASCULAR AGENT; CLONAZEPAM; CONTRACEPTIVE AGENT; DILTIAZEM; EPITEC; EPITOZ; EPLEPTIN; ETHOSUXIMIDE; ETIRACETAM; GABAPENTIN; IMMUNOSUPPRESSIVE AGENT; LAMICTIN; LAMIDUS; LAMITOR; LAMOTRIGINE; LETHYL; MACROLIDE; MANNOMUSTINE; NEUREXAL; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PIRAMAX; PREGABALIN; PRIMIDONE; PSYCHOTROPIC AGENT; RAN GABAPENTIN; TIAGABINE; TOPIRAMATE; TOPLEP; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL; VIGABATRIN; VITALET; ZONISAMIDE;

ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; AGGRESSION; AGGRESSIVENESS; AGING; AKATHISIA; ALCOHOL WITHDRAWAL; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANGIOGENESIS; ANOREXIA; ANXIETY; ANXIETY DISORDER; APOPTOSIS; ASTHMA; BEHAVIOR DISORDER; BINGE EATING DISORDER; BIPOLAR DISORDER; BLINDNESS; BORDERLINE STATE; BRAIN FUNCTION; BRAIN INFARCTION; BREAST CANCER; BULIMIA; CELL CYCLE; CHOREA; CHROMATIN; CLINICAL FEATURE; COCAINE DEPENDENCE; COGNITIVE DEFECT; DAYTIME SEDATION; DEACETYLATION; DEPRESSION; DIABETIC NEUROPATHY; DIARRHEA; DIZZINESS; DNA TRANSCRIPTION; DOPAMINERGIC ACTIVITY; DRUG EFFICACY; DRUG ERUPTION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DYSTONIA; EMOTIONAL DISORDER; ENDOCRINE FUNCTION; ENDOMETRIUM CANCER; ESSENTIAL TREMOR; EVIDENCE BASED PRACTICE; EXTRAPYRAMIDAL SYNDROME; FIBROMYALGIA; GABAERGIC TRANSMISSION; GENE SILENCING; GLIOBLASTOMA; GUM OVERGROWTH; HAIR LOSS; HIRSUTISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS NEUROPATHY; HYPERACTIVITY; HYPERALGESIA; HYPERAMMONEMIA; HYPERSALIVATION; HYPERSENSITIVITY REACTION; HYPONATREMIA; IMPULSE CONTROL DISORDER; IMPULSIVENESS; INFLAMMATION; INSOMNIA; IRRITABILITY; KLEPTOMANIA; LEUKOPENIA; LIFESPAN; LIVER METABOLISM; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MELANOMA; MENTAL DISEASE; METABOLIC CLEARANCE RATE; MIGRAINE; MYOCLONUS; NAUSEA; NEMATODE; NEPHROLITHIASIS; NERVE CELL NETWORK; NERVE POTENTIAL; NERVOUSNESS; NEUROLOGIC DISEASE; NEUROMUSCULAR DISEASE; NEUROPATHIC PAIN; NEUROPATHY; NEUROPROTECTION; NOCICEPTION; OFF LABEL DRUG USE; PAIN THRESHOLD; PANCREATITIS; PARESTHESIA; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; POSTHERPETIC NEURALGIA; PROPHYLAXIS; PROSTATE CANCER; PSYCHOSIS; RASH; RESTLESS LEGS SYNDROME; REVIEW; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; SOCIAL PHOBIA; SPEECH DISORDER; SUBSTANCE ABUSE; TARDIVE DYSKINESIA; THROMBOCYTOPENIA; TREMOR; TRICHOTILLOMANIA; TRIGEMINUS NEURALGIA; TUMOR GROWTH; VASODILATATION; VISUAL FIELD DEFECT; WEIGHT GAIN; WEIGHT REDUCTION; WITHDRAWAL SYNDROME;

EID: 77953693155     PISSN: 10151362     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. McNamara J O. 2005. Chapter 19. Pharmacotherapy of the Epilepsies In: Brunton LL, Lazo JS, Parker KL (Eds): Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th Edition: The McGraw-Hill Companies Inc., New York.
2. Rogawski MA and Loscher W. 2004. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nature Medicine 10(7):685-692 (Pubitemid 38937632)
3. Porter RJ, Meldrum BS. 2009. Chapter 24. Antiseizure Drugs In: Katzung BG (Ed): Basic & Clinical Pharmacology, 11th Edition: The McGraw-Hill Companies Inc., New York.
4. Stahl SM. 2008. Chapter 5: Ion Channels and Enzymes as Targets of Psychopharmacological Drug Action. In: Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 3rd Edition. Cambridge University Press, New York.
5. Eisenberg E, River Y, Shifrin A, Krivoy N. 2007. Antiepileptic drugs in the treatment of neuropathic pain. Drugs. 67(9):1265-89. (Pubitemid 46879094)
6. Dworkin RH, O'Connor AB, Audette J, et al. 2010. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 85(3 Suppl):S3-14.
7. Paster Z, Morris CM. 2010. Treatment of the localized pain of postherpetic neuralgia. Postgrad Med. 122(1):91-107.
8. Namaka M, Leong C, Grossberndt A, et al. 2009. A treatment algorithm for neuropathic pain: an update. Consult Pharm. 24(12):885-902.
9. Goodyear-Smith F, Halliwell J. 2009. Anticonvulsants for neuropathic pain: Gaps in the evidence. Clin J Pain 25(6):528-536
10. Simpson DM, Schifitto G, Clifford DB, et al. 2010. Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial. Neurology. 74(5):413-20.
11. Simpson DM, McArthur JC, Olney R, et al. 2003. Lamotrigine forHIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology. 60(9):1508-14.
12. Martella G, Costa C, Pisani A, Cupini LM, Bernardi G, Calabresi P. 2008. Antiepileptic drugs on calcium currents recorded from cortical and PAG neurons: Therapeutic implications for migraine. Cephalalgia. 28(12):1315-26
13. Calabresi P, Galletti F, Rossi C, Sarchielli P, Cupini LM. 2007. Antiepileptic drugs in migraine: from clinical aspects to cellular mechanisms. Trends Pharmacol Sci. 28(4):188-95 (Pubitemid 46505168)
14. Marcus DA. 2009. Fibromyalgia: Diagnosis and Treatment Options. Gender Medicine 6[Theme Issue]:139-151
15. Spina E, Perugi G. 2004. Antiepileptic drugs: indications other than epilepsy. Epileptic Disord. 6(2):57-75. (Pubitemid 38808120)
16. Gemignani F, Brindani F, Vitetta F, Marbini A. 2009. Restless legs syndrome and painful neuropathy-retrospective study. A role for nociceptive deafferentation? Pain Med. 10(8):1481-6.
17. Jimenez-Trevino L. 2009. Oxcarbazepine Treatment of Restless Legs Syndrome. Clin Neuropharm. 32(3):169-170
18. Johannessen Landmark C. 2008. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs. 22(1):27-47. (Pubitemid 350243365)
19. Mantegazza M, Curia G, Biagini G, Ragsdale DS, Avoli M. 2010. Voltagegated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol. 9(4):413-24.
20. Monti B, Polazzi E, Contestabile A. 2009. Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection. Curr Mol Pharmacol. 2(1):95-109.
21. Bowden C. 2009. Anticonvulsants in bipolar disorders: current research and practice and future directions. Bipolar Disorders 11 Suppl 2:20-33
22. Gajwani P, Forsthoff A, Muzina D, et al. 2005. Antiepileptic drugs in mood-disordered patients. Epilepsia. 46 Suppl 4:38-44.
23. Malhi GS, Adams D, Cahill CM, Dodd S, Berk M. 2009. The management of individuals with bipolar disorder: a review of the evidence and its integration into clinical practice. Drugs. 69(15):2063-101.
24. Fountoulakis KN. 2010. An update of evidence-based treatment of bipolar depression: where do we stand? Curr Opin Psychiatry. 23(1):19-24.
25. Crepeau AZ, Treiman DM. 2010. Levetiracetam: a comprehensive review. Expert Rev Neurother. 10(2):155-7.
26. Van Ameringen M, Mancini C, Pipe B, Bennett M. 2004. Antiepileptic drugs in the treatment of Anxiety disorders. Drugs. 64(19):2199-2220
27. Bandelow B, Wedekind D, Leon T. 2007. Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention. Expert Rev Neurother. 7(7):769-81.
28. Rocamora R, Sánchez-Alvarez JC, Salas-Puig J. 2008. The relationship between sleep and epilepsy. Neurologist. 14(6 Suppl 1):S35-43.
29. Lo HS, Yang CM, Lo HG, Lee CY, Ting H, Tzang BS. 2010. Treatment effects of gabapentin for primary insomnia. Clin Neuropharmacol. 33(2):84-90
30. Ettinger AB, Argoff CE. 2007. Use of antiepileptic drugs for nonepileptic conditions: psychiatric disorders and chronic pain. Neurotherapeutics. 4(1):75-83
31. Gentry JR, Hill C, Malcolm R. 2002. New anticonvulsants: a review of applications for the management of substance abuse disorders. Ann Clin Psychiatry. 14(4):233-45. (Pubitemid 36231916)
32. Berlin H. 2008. Antiepileptic Drugs for the Treatment of Impulsivity. Curr Psych Rev 4:114-136
33. McElroy SL, Guerdjikova AI, Martens B, Keck PE Jr, Pope HG, Hudson JI. 2009. Role of antiepileptic drugs in the management of eating disorders. CNS Drugs. 23(2):139-56.
34. Venkataramani V, Rossner C, Iffland L, et al. 2010. Histone Deacetylase Inhibitor Valproic Acid Inhibits Cancer Cell Proliferation via Down-regulation of the Alzheimer Amyloid Precursor Protein. Journal of Biological Chemistry, 285:10678-10689.
35. McIntyre, J., Moral, M.A., Bozzo, J. 2007. Combination therapy with valproic acid in cancer: Initial clinical approach. Drugs Fut 32(1): 45
36. Evason K, Huang C, Yamben I, Covey DF, Kornfeld K. 2005. Anticonvulsant medications extend worm life-span. Science. 307(5707):258-62. (Pubitemid 40116241)
37. Collins JJ, Evason K, Pickett CL, Schneider DL, Kornfeld K. 2008. The anticonvulsant ethosuximide disrupts sensory function to extend C. elegans lifespan. PLoS Genet. 4(10):e1000230. Epub 2008 Oct 24.
38. Perucca E . 2006. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 61(3): 246-255. (Pubitemid 43382623)
39. Perucca P, Carter J, Vahle V, Gilliam FG. 2009. Adverse antiepileptic drug effects: Toward a clinically and neurobiologically relevant taxonomy. Neurology 72(14):1223-1229
40. Greenwood RS. 2000. Adverse effects of antiepileptic drugs. Epilepsia 41(Suppl. 2):S42-S52
41. Jeffrey F. Wade, Chat V. Dang, Lowell Nelson, Jonathan Wasserberger. 2010. Emergent Complications of the Newer Anticonvulsants. J Emerg Med 38(2):231-237
42. FDA Statistical Review and Evaluation of Antiepileptic Drugs and Suicidality. http://www.fda.gov/downloads/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/UCM192556.pdf Accessed 29 March 2010
43. Drugs That Treat Epilepsy Linked to Suicide. CNN Editorial: http://edition.cnn.com/2010/HEALTH/04/13/depression.drugs.suicide.risk/index. html?hpt=T2 Accessed 16 April 2010